Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.
USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.
Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.
Market Analysis and Insights: Global and China Humira Market
This report focuses on global and China Humira market.
In 2020, the global Humira market size was US$ 17920 million and it is expected to reach US$ 10150 million by the end of 2027, with a CAGR of -8.3% during 2021-2027. In China the Humira market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Humira Scope and Market Size
Humira market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Humira market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Humira market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
Humira Syringe
Humira Pen
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn's disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.
USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.
Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.
Market Analysis and Insights: Global and China Humira Market
This report focuses on global and China Humira market.
In 2020, the global Humira market size was US$ 17920 million and it is expected to reach US$ 10150 million by the end of 2027, with a CAGR of -8.3% during 2021-2027. In China the Humira market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Humira Scope and Market Size
Humira market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Humira market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Humira market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
Humira Syringe
Humira Pen
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.